Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
November 30, 2021
10:07 am ET
*ContraFect Shares Halted On Circuit Breaker To Upside; Up 14%
Benzinga
10:07 am ET
Watching ContraFect Shares; Zacks Small-Cap Research Sets $23 Valuation
Benzinga
Far out!
4.38 -4.45 resistance, may cut thru like butter!
CFRX 3.68 HALTED UP
watching this consolidation closely. Building my position 3.15 to 3.30.
Bring Santa on the set by Friday!!
Back in 3.27. Didn't mention my sell so I won't post the price. Earnings are almost always good for a pull back. Was thinking closer to $3 so we'll get another dip next week or this proves a bottom.
GLTA
Prev Close3.29
Today's Open3.27
Day's Range3.24-3.31
Avg Vol (10-day)127.9K
Last (time)2:37p ET 11/19/21
Last (size)494
52-Wk Range
3.10 - 7.63LowHigh
% Above Low (03/12/21 - 08/18/21)5.48%
Historical Volatility62.8%
Market Cap128.6M
Shares Outstanding39.3M
EPS (TTM, GAAP)-0.68
P/E Ratio (TTM, GAAP)--
Annual Dividend/YieldNo dividend
Ex-dividend DateNo dividend
Dividend Pay DateNo dividend
Beta0.8
% Held by Institutions60.66
Short Interest (% of float 10/29/21)
Sensing some upgrades here. Just a BooDog gut feeling.
This was back in August...
ContraFect Shares See Volume; Zacks Small-Cap Research Sets $23 Price Target
11:11 am ET August 30, 2021 (Benzinga) Print
Latest Ratings for CFRX DateFirmActionFromTo
Mar 2021WBB SecuritiesInitiates Coverage OnSpeculative Buy Jun 2020Cantor FitzgeraldInitiates Coverage OnOverweight Jun 2020MizuhoInitiates Coverage OnBuy
View More Analyst Ratings for CFRX
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Keeping some cash on the side if it decides to go even lower. Not selling anything. But was very tempted in the 3.60's.
Good luck!
I snagged some at about $3.80 at the open,... apparently I should have waited until this afternoon,... Cest la vie? I was planning on holding my shares for a while anyway,...
Took a bite. 3.80. This may not be bottom though like the tease on the 50 DMA for a possible bounce. Keeping some cash reserved just in case.
CFRX daily
Anything under $4 and I’m adding
Interesting information - thanks. I'll have to look in on that one.
Along with Contrafect, I'm also invested in another company called Armata Pharmaceuticals (ARMP) that is also working on treatments for antibiotic resistant bacteria. The difference, as I understand it, is that ARMP is using a class of viruses called phages, that commonly occur naturally in our environment and attack bacteria, as an injectable treatment. Contrafect is also researching phages, but instead of injecting the virus into patients, they are developing drugs based how these viruses destroy bacteria. While Armata may have an edge in flexibility of finding different viruses that can be used to attack different bacterial diseases, Patients and doctors may find using a drug treatment preferable to injecting live virus into a human. I think both approaches could be viable. Contrafect seems to be a step ahead on clinical trials...
Scientists Are Using a New Weapon to Fight Drug-Resistant Bacteria—Viruses
IMO your friend's assessment is very correct. Antibiotic resistant bacteria are not going away, and almost nobody has discovered a new 'class' of antibiotics and made that work.
These lysins are probably going to be useful, and not a lot of companies are working on useful alternatives. Several years ago I had a small investment in a now-bankrupt company (AKAO) that had a new antibiotic in the aminoglycoside (think streptomycin-like) class that looked fairly promising in clinical trials as a treatment for hospitalized folks with antibiotic-resistant strains of bacteria.
They also had some pre-clinical 'unconventional' anti-bacterial compounds further down the pipeline, but obviously that work all ended when the company went belly-up. Small company even got it's drug approved, but didn't have the capital to get it to market effectively.
I make a small profit on that one, but not much. And lots of other folks lost a lot.
I had a friend who died like 4 years ago. He had done some contractual work for Contrafect years earlier and told me if the company ever got their sh** together and could get their main formula approved, it would be high flyer….
Have been lurking around here for a while now,....
Cheers!
Phase II testing is just that - Phase II testing. Until this company gets something completely past a Phase III and are preparing their BLA and data package to the FDA,... they are still a risky (risk is a two sided sword) bet.
Now - that having been said - CFRX has narrowed the range of that risk considerably by having what appear to be quite successful Phase II clinical results,...
That also having been said - I'll be looking to opportunistically add sets of shares here, and at a couple of other similarly positioned biotech companies through the winter. I don't really trade in and out much. I just find something that looks like it has some potential a year or so down the road, buy some of it cheap, and sit on it for a while.
Still going down, TLV. Your predictions are as good as mud, eight months later. From $5.24 to 4.00!
Let's see the volume kick in! https://finance.yahoo.com/news/contrafect-phase-2-exebacase-data-130000870.html
With everything going on the past 18 months or so I think it's still likely they will manage to post data, likely in December.
hope we get futility results this quarter
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
September 29 2021 - 07:30AM
GlobeNewswire Inc.
ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to deliver a Late Breaker oral presentation on the rapid symptom resolution in adult patients with Staphylococcus aureus (Staph aureus) bacteremia who were treated with exebacase in the completed Phase 2 study.
The company will also present the results of a recently conducted microbiologic surveillance study of the activity of exebacase (CF-301) against Staph aureus specimens from patients with bacteremia in the United States, including multidrug-resistant Methicillin-resistant Staph aureus (MRSA) species.
These findings are all being presented at IDWeekTM 2021, being held from September 29 through October 3, in San Diego, CA.
IDWeekTM 2021 Presentation Details:
Oral Late-Breaker presentation:
Abstract: Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia
Session: Late Breaker Abstracts
Date: Saturday October 2, 2021
Session Time: 1:15 PM – 3:00 PM
Presenting Author: Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research & Development, ContraFect
Poster presentation:
Session: Novel Agents
Poster Title: In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets
Poster ID: 1059
Presenting Author: Rodrigo Mendes, Ph.D. (JMI Laboratories)
All posters will be available to meeting registrants on demand and available through the IDWeek website. Following the meeting, the presentation abstracts and poster will be available on the ContraFect website.
About Exebacase (CF-301):
Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. In the Company’s Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates. Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.
Exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia. Exebacase was licensed from The Rockefeller University and is being developed at ContraFect.
About ContraFect
ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: exebacase data and its clinical utility, the presentations, ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect’s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect’s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption “Risk Factors” in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts:
Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
mmessinger@contrafect.com
Jules Abraham
CORE IR
Tel: 917-885-7378
Julesa@coreir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2021 to Sep 2021
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2020 to Sep 2021
Latest CFRX Messages
BooDog Wed Sep 29, 2021 8:01 AM (5 minutes ago)And glad I put it back in yesterdayBooDog Tue Sep 28, 2021 10:05 AM (22 hours ago)Took a chunk off yesterday near the top,BooDog Mon Sep 27, 2021 1:51 PM (1 day ago)Could be this is just getting started.trickledownfacists Mon Sep 27, 2021 10:46 AM (1 day ago)Yuptrickledownfacists Thu Sep 23, 2021 3:35 PM (5 days ago)Back over $4trickledownfacists Thu Sep 16, 2021 5:10 PM (12 days ago)Yuptrickledownfacists Tue Sep 14, 2021 2:29 PM (14 days ago)Tick tocktrickledownfacists Thu Sep 9, 2021 3:23 PM (19 days ago)Chuggin away…..lesgetrich Thu Sep 9, 2021 11:05 AM (19 days ago)Zacks Small Cap Research set a price targetBooDog Wed Sep 8, 2021 1:26 PM (20 days ago)My chart felt it coming...
See More Posts on CFRX Message Board
Support: 888-992-3836
By accessing the services available at InvestorsHub you are agreeing to be bound by InvestorsHub's Terms of Service.
Terms of Service Disclaimer Cookie and Privacy Policy Data Accreditations Advertise With Us
And glad I put it back in yesterday too! Should have put even more in. Never seem to thave enough of something that's moving in the right direction!
Took a chunk off yesterday near the top, was thinking it would reset.
Thanks for being my new ATM CFRX!!!!
When this puppy takes off it's gonna move quickly imo. But in the meantime, a few .20 + swings keeps things interesting.
Could be this is just getting started.
https://stockcharts.com/h-sc/ui?s=CFRX&p=D&yr=0&mn=3&dy=10&id=p65522696115&a=870870209
Zacks Small Cap Research set a price target of $23/share for ContraFect on 8/30/21
Today Leerink initiated coverage on ContraFect with an Outperform rating and a price target of $14/share.
Good time to load up.
My chart felt it coming...
Filled Buy xxxx CFRX Limit 3.76, locked in some green to let the rest ride the wave.
CFRX daily Look closer for the 4.40 - 4.50 resistance. 4.60's + should slice through like a summer ripe peach with some decent action.
GLTA
$CFRX
This gets some volume behind it it'll see more than $4 imo.
Curious to hear how their expanded access study has been going. If at all.
https://clinicaltrials.gov/ct2/history/NCT04597242?V_3=View#StudyPageTop
Has the cup, needs the handle and some volume to go with it.
imo
SONN daily
Need the small squeeze to turn into THE BIG SQUEEZE!!
Good move imo. stocks posting earnings on a hot summer Friday, barely any volume. A sitting duck.
Hopefully a few more months for the futility data and then this will get her sea legs.
Already making round trips with this one. Thinking this will surprise but... as this nears earnings it may still see a dip.
Annual Earnings Beat Consensus (Year ending 12/2020) Next Earnings Announcement
Annual Non-GAAP earnings
Announced March 30, 2021 -$1.24 Annual Consensus
of 3 analysts -$1.53 Difference from
consensus
23.23%
2021 Earnings
will announce (Unconfirmed) August 13, 2021
I have a core position but will be watching closely to see how this reacts.
I'm thinking this'll be at least a 4 bagger.
Do your DD as always.
https://www.contrafect.com/
https://finviz.com/quote.ashx?t=cfrx
"only pay for what you need"
Translation..... no risk, no reward. BE THE OSTRICH!!!
Followers
|
45
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
580
|
Created
|
03/15/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |